U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H25N4O8.Gd
Molecular Weight 558.64
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GADOTERIC ACID

SMILES

[Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1

InChI

InChIKey=GFSTXYOTEVLASN-UHFFFAOYSA-K
InChI=1S/C16H28N4O8.Gd/c21-13(22)9-17-1-2-18(10-14(23)24)5-6-20(12-16(27)28)8-7-19(4-3-17)11-15(25)26;/h1-12H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3

HIDE SMILES / InChI

Molecular Formula Gd
Molecular Weight 157.25
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H25N4O8
Molecular Weight 401.3917
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7960618; https://www.ncbi.nlm.nih.gov/pubmed/?term=23435930; http://mnoncology.com/disease-drug-info/drug-dictionary/G/

DOTAREM (Gadoterate Meglumine ) is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associatedtissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity. Gadoterate Meglumine is a gadolinium chelate paramagnetic contrast agent. When placed in a magnetic field, gadoterate meglumine produces a large magnetic moment and so a large local magnetic field, which can enhance the relaxation rate of nearby protons; as a result, the signal intensity of tissue images observed with magnetic resonance imaging (MRI) may be enhanced. Because this agent is preferentially taken up by normal functioning hepatocytes, normal hepatic tissue is enhanced with MRI while tumor tissue is unenhanced. In addition, because gadobenate dimeglumine is excreted in the bile, it may be used to visualize the biliary system using MRI.

CNS Activity

Curator's Comment: Gadoterate does not cross the intact blood-brain barrier and, therefore, does not enhance normal brain or lesions that have a normal blood-brain barrier, e.g. cysts, mature post-operative scars. However, disruption of the bloodbrain barrier or abnormal vascularity allows distribution of gadoterate in lesions such as neoplasms, abscesses, and infarcts.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P27169
Gene ID: 5444.0
Gene Symbol: PON1
Target Organism: Homo sapiens (Human)
105.0 mM [Ki]
Target ID: P52209
Gene ID: 5226.0
Gene Symbol: PGD
Target Organism: Homo sapiens (Human)
73.0 mM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
DOTAREM

Approved Use

Indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Launch Date

1.36373758E12
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

1.30006083E12
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

1.30006083E12
Diagnostic
GADAVIST

Approved Use

Gadavist is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates); to assess the presence and extent of malignant breast disease; to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients (including term neonates) disease.

Launch Date

1.30006083E12
PubMed

PubMed

TitleDatePubMed
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.
2001 Feb 16
Extracellular calcium-sensing receptor is expressed in rat hepatocytes. coupling to intracellular calcium mobilization and stimulation of bile flow.
2001 Feb 9
Diacylglycerol activates the influx of extracellular cations in T-lymphocytes independently of intracellular calcium-store depletion and possibly involving endogenous TRP6 gene products.
2002 May 15
Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing.
2005 Apr 20
Dissociation of regulated trafficking of TRPC3 channels to the plasma membrane from their activation by phospholipase C.
2006 Apr 28
Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures.
2006 Feb
Suggesting gadolinium-based contrast media for CT in azotemic patients is not based on historical, clinical, and experimental data.
2007 Aug
Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
2008 Apr
Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors.
2008 Aug
Metabotropic receptor-activated calcium increases and store-operated calcium influx in mouse Müller cells.
2008 Jul
Renal failure and gadolinium. The number of documented cases is rising.
2008 Oct
Use of gadolinium for carotid artery angiography and stenting in patients with renal insufficiency.
2009 Dec
Release of ATP from rat urinary bladder mucosa: role of acid, vanilloids and stretch.
2009 Dec
Large sample of nephrogenic systemic fibrosis cases from a single institution.
2009 Oct
Impaired mitochondrial function and oxidative stress in rat cortical neurons: implications for gadolinium-induced neurotoxicity.
2010 Aug
Patents

Sample Use Guides

Recommended dose for adults and pediatric patients (including term neonates) is 0.1 mL/kg body weight. Administer as an intravenous bolus injection. Follow injection with a normal saline flush.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:02:35 UTC 2023
Edited
by admin
on Fri Dec 15 16:02:35 UTC 2023
Record UNII
QVF9Y6955W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GADOTERIC ACID
INN   MART.   WHO-DD  
INN  
Official Name English
GADOTERATE
Common Name English
Gadoteric acid [WHO-DD]
Common Name English
HYDROGEN (1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETATO(4-))GADOLINATE(1-)
Common Name English
GADOTERIC ACID [MART.]
Common Name English
gadoteric acid [INN]
Common Name English
GADOTERIC ACID [MI]
Common Name English
ARTIREM
Brand Name English
Classification Tree Code System Code
WHO-ATC V08CA02
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
WHO-VATC QV08CA02
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
Code System Code Type Description
INN
6253
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
EPA CompTox
DTXSID801027873
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
PUBCHEM
158536
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
MERCK INDEX
m11732
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
NCI_THESAURUS
C174900
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
CHEBI
73732
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
LACTMED
Gadoterate
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
EVMPD
SUB07865MIG
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
FDA UNII
QVF9Y6955W
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
CAS
72573-82-1
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
CAS
131330-52-4
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
ALTERNATIVE
WIKIPEDIA
GADOTERIC ACID
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
DRUG BANK
DB09132
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
SMS_ID
100000089855
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
DRUG CENTRAL
4559
Created by admin on Fri Dec 15 16:02:35 UTC 2023 , Edited by admin on Fri Dec 15 16:02:35 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY